In a study published in Molecular Cell, researchers at UCSF captured six structural states of PI3Kα as it progressed through different stages of activation. The work, led by first author Hayarpi Torosyan and senior authors Natalia Jura and Kliment Verba, provides new insight into how this enzyme integrates multiple cellular signals to regulate growth and survival.

PI3Kα plays a central role in helping cells respond to external signals that control growth, metabolism, and survival. Under normal conditions, the protein remains tightly regulated, switching on only when needed. However, mutations that increase PI3Kα activity are among the most common genetic alterations found in human cancers, making it an important focus of cancer research and drug development.

Although scientists have studied PI3Kα for decades, many details of how it becomes activated at the cell membrane have remained unclear. Previous studies had captured the protein in inactive or partially activated states, but researchers lacked a detailed view of how PI3Kα interacts with cellular membranes, upstream activators, and its lipid substrate during activation.

To investigate these questions, the team reconstructed PI3Kα in membrane-like environments known as lipid nanodiscs and visualized the resulting complexes using cryo-electron microscopy. They determined six structures representing different stages of activation and visualized how PI3Kα responds to upstream cellular signals, including KRas, membrane lipids, and growth factor receptor-derived phosphopeptides.

The structures showed that PI3Kα activation occurs through a series of coordinated molecular rearrangements. As the protein engages with the membrane and activating partners, inhibitory regions gradually move away from the catalytic core, allowing PI3Kα to adopt increasingly active conformations.

The researchers also found that PIP2, the lipid molecule modified by PI3Kα, contributes directly to the activation process. Binding of PIP2 fully disinhibited the enzyme and reorganized key regulatory regions positioning them for catalytic activity. The findings suggest that even after being recruited to the membrane by Ras, PI3Kα traverses the membrane in potentiated but not fully active state, only being activated upon encountering a pool of PIP2. 

In addition to identifying intermediate activation states, the researchers discovered that activated PI3Kα molecules can pair together to form dimers. Experiments in human cells showed that disrupting this newly identified dimerization interface reduced activation of the downstream Akt signaling pathway, indicating that dimer formation helps strengthen cellular growth signals following stimulation by growth factors.

The study also provides new insight into H1047R, one of the most common cancer-associated mutations in PI3Kα. The structural data suggest that this mutation disrupts interactions that normally help keep the protein in an inactive state, making it easier for PI3Kα to adopt active conformations and promote signaling.

Together, the findings provide a structural framework for understanding how PI3Kα integrates multiple signals to achieve full activation. By identifying structural states associated with activation and dimerization, the study offers new insight into how normal growth signaling is regulated and how these processes can become dysregulated in cancer. The work also identifies previously uncharacterized protein interfaces that could be explored in future efforts to develop more selective therapies targeting the PI3K signaling pathway.